Eunice Wang, MD, Roswell Park Comprehensive Cancer Center, Buffalo, NY, shares some updates from the Phase I/II KOMET-001 trial (NCT04067336), which is evaluating ziftomenib, a novel menin inhibitor, in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) with specific molecular subtypes, namely KMT2A and NPM1 mutation. This interview took place at the 64th ASH Annual Meeting and Exposition congress held in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.